Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Arrowhead Pharmaceuticals Inc (ARWR)  
$22.12 0.25 (1.14%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 102,290,000
Market Cap: 2.26(B)
Last Volume: 372,414 Avg Vol: 371,375
52 Week Range: $21.2 - $41.38
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Business Services

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ INDUSTRIAL

Rankings:
     
Insider 3 Months    : 7
Insider 6 Months    : 7
Insider 3/6 Months : 14.3
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of RNA chemistries and several modes of delivery, Co.'s therapies trigger the RNA interference (RNAi) mechanism to induce knockdown of target genes. Co. is focused on developing drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. Co.'s pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, and ARO-DUX4 for facioscapulohumeral muscular dystrophy.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 3,000 3,000 3,000 3,000
Total Buy Value $82,990 $82,990 $82,990 $82,990
Total People Bought 1 1 1 1
Total Buy Transactions 3 3 3 3
Total Shares Sold 103,499 263,917 485,913 579,301
Total Sell Value $3,435,799 $8,844,396 $16,454,910 $19,827,309
Total People Sold 3 10 10 11
Total Sell Transactions 3 19 28 35
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 361
  Page 2 of 15  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hamilton James C Chief Discovery/Trans Medicine   –       –      –    2024-01-03 4 AS $31.81 $202,781 D/D (6,300) 175,934 -31%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2024-01-02 4 AS $30.74 $308,637 D/D (9,952) 3,715,048 -29%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-12-20 4 AS $28.54 $342,480 D/D (12,000) 3,725,000 -21%     
   Waddill William D. Director   –       •      –    2023-12-15 4 A $25.41 $380,820 D/D 14,987 51,804     -
   Ferrari Mauro Director   –       •      –    2023-12-15 4 A $25.41 $380,820 D/D 14,987 65,825     -
   Perry Michael S Director   –       •      –    2023-12-15 4 A $25.41 $380,820 D/D 14,987 114,754     -
   Given Douglas B Director   –       •      –    2023-12-15 4 A $25.41 $380,820 D/D 14,987 132,622     -
   Olukotun Adeoye Y Director   –       •      –    2023-12-15 4 A $25.41 $380,820 D/D 14,987 22,854     -
   Vakiener Victoria Director   –       •      –    2023-12-15 4 A $25.41 $380,820 D/D 14,987 36,721     -
   San Martin Javier Chief Medical Officer   •       –      –    2023-11-20 4 S $28.73 $567,315 D/D (19,700) 131,800 9%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-10-25 4 AS $24.21 $589,223 D/D (24,338) 3,737,000 48%     
   Vakiener Victoria Director   –       •      –    2023-09-28 4 S $26.33 $40,812 D/D (1,550) 21,734 -18%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-09-18 4 AS $28.00 $1,624,223 D/D (57,755) 3,761,338 16%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-09-18 4 OE $4.75 $274,336 D/D 57,755 3,819,093     -
   Oliver Tracie Chief Commercial Officer   •       –      –    2023-07-03 4 S $35.31 $315,142 D/D (8,925) 61,575 23%     
   Hamilton James C Chief Discovery/Trans Medicine   –       –      –    2023-06-30 4 S $35.53 $106,590 D/D (3,000) 188,484 23%     
   Myszkowski Kenneth Allen Chief Financial Officer   •       –      –    2023-06-27 4 S $36.20 $543,000 D/D (15,000) 381,704 27%     
   Given Douglas B Director   –       •      –    2023-05-05 4 S $40.90 $265,850 D/D (6,500) 117,635 26%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-05-04 4 S $38.97 $1,975,792 D/D (50,000) 3,761,338 27%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-05-04 4 OE $2.01 $100,500 D/D 50,000 3,811,338     -
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-05-03 4 S $39.14 $2,149,882 D/D (54,928) 3,761,338 28%     
   Anzalone Christopher Richard Chief Executive Officer   •       •      –    2023-05-03 4 OE $2.01 $110,405 D/D 54,928 3,816,266     -
   Olukotun Adeoye Y Director   –       •      –    2023-03-03 4 S $32.65 $370,578 D/D (11,350) 7,867 -7%     
   Given Douglas B Director   –       •      –    2023-02-27 4 S $32.62 $28,543 I/I (875) 13,000 -2%     
   Ferrari Mauro Director   –       •      –    2023-01-10 4 A $0.00 $0 D/D 7,867 50,838     -
  361 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 15
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us